Show simple item record

dc.contributor.authorDormond, Olivier*
dc.date.accessioned2021-02-11T20:17:42Z
dc.date.available2021-02-11T20:17:42Z
dc.date.issued2019*
dc.date.submitted2019-06-26 08:44:06*
dc.identifier33689*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/54029
dc.description.abstractThe mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies.*
dc.languageEnglish*
dc.subjectR5-920*
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.othern/a*
dc.subject.otherprimary cilia*
dc.subject.otherneurodegeneration*
dc.subject.othernutrient sensor*
dc.subject.otherPI3K*
dc.subject.othertranscriptomics*
dc.subject.otherphosphorylation*
dc.subject.othermetabolic reprogramming*
dc.subject.otherautophagy*
dc.subject.otherAlzheimer’s disease*
dc.subject.otherrapalogs*
dc.subject.otherliver*
dc.subject.otherangiogenesis*
dc.subject.othermTOR complex*
dc.subject.otherMBSCs*
dc.subject.otheradvanced biliary tract cancers*
dc.subject.otherMedulloblastoma*
dc.subject.otherepithelial to mesenchymal transition*
dc.subject.otherAMPK*
dc.subject.otherp70S6K*
dc.subject.otherlipid metabolism*
dc.subject.otherthyroid cancer*
dc.subject.othersodium iodide symporter (NIS)/SLC5A5*
dc.subject.othermale fertility*
dc.subject.otheranesthesia*
dc.subject.otherillumina*
dc.subject.othermTOR inhibitor*
dc.subject.othermiRNA*
dc.subject.otherHutchinson-Gilford progeria syndrome (HGPS)*
dc.subject.othereIFs*
dc.subject.otherEmery-Dreifuss muscular dystrophy (EDMD)*
dc.subject.otherglucose*
dc.subject.otherAKT*
dc.subject.otheroral cavity squamous cell carcinoma (OSCC)*
dc.subject.otherglucose and lipid metabolism*
dc.subject.othercellular signaling*
dc.subject.otheraging*
dc.subject.othertumor microenvironment*
dc.subject.otherrapamycin*
dc.subject.otherleukemia*
dc.subject.otherchloral hydrate*
dc.subject.otherrapalogues*
dc.subject.otherschizophrenia*
dc.subject.otherT-cell acute lymphoblastic leukemia*
dc.subject.othersenescence*
dc.subject.otherlamin A/C*
dc.subject.otherneurotoxicity*
dc.subject.otherneurodevelopment*
dc.subject.otherinhibitor*
dc.subject.othermethamphetamine*
dc.subject.otherpulmonary fibrosis*
dc.subject.othermTOR*
dc.subject.othermTOR inhibitors*
dc.subject.othercombination therapy*
dc.subject.otherproteolysis*
dc.subject.otherfluid shear stress*
dc.subject.othertumour cachexia*
dc.subject.otherbiomarkers*
dc.subject.othersynapse*
dc.subject.othergluconeogenesis*
dc.subject.othermTOR signal pathway*
dc.subject.otherSertoli cells*
dc.subject.otherimmunosenescence*
dc.subject.othermiRNome*
dc.subject.otherprotein aggregation*
dc.subject.othersenolytics*
dc.subject.othermetabolism*
dc.subject.otherNGS*
dc.subject.othermTORC2*
dc.subject.othermTORC1*
dc.subject.othermetabolic diseases*
dc.subject.otherIonTorrent*
dc.subject.otherapoptosis*
dc.subject.otherdopamine receptor*
dc.subject.othernocodazole*
dc.subject.othermicroenvironment*
dc.subject.othereverolimus*
dc.subject.otheracute myeloid leukemia*
dc.subject.otherimmunotherapy*
dc.subject.otherspermatogenesis*
dc.subject.otherbone remodeling*
dc.subject.othersignalling*
dc.subject.othertargeted therapy*
dc.subject.otherageing*
dc.subject.othertherapy*
dc.subject.otherNVP-BEZ235*
dc.subject.otherfructose*
dc.subject.otherphysical activity*
dc.subject.otherlaminopathies*
dc.subject.otherMC3T3-E1 cells*
dc.subject.othercell signaling*
dc.subject.othermicroRNA*
dc.subject.othercancer*
dc.subject.otherlipolysis*
dc.subject.othermelatonin*
dc.subject.otherParkinson’s disease*
dc.titlemTOR in Human Diseases*
dc.typebook
oapen.identifier.doi10.3390/books978-3-03921-061-9*
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
oapen.relation.isbn9783039210619*
oapen.relation.isbn9783039210602*
oapen.pages480*
oapen.edition1st*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/